| |
76
|
76.2
|
76.3
|
76.4
|
|---|
| |
HeLa
|
TERT
|
HeLa
|
TERT
|
HeLa
|
TERT
|
HeLa
|
TERT
|
|---|
|
25 μM
|
20.1 ± 5.2#
|
21.7 ± 3.6#
|
73.7 ± 12.6
|
81.0 ± 8.1
|
58.2 ± 7.4#
|
112.9 ± 19.1
|
53.7 ± 6.0#
|
120.0 ± 26.5
|
|
50 μM
|
20.4 ± 4.1#
|
23.5 ± 12.0*
|
31.2 ± 12.9#
|
16.2 ± 4.0#
|
40.1 ± 8.0#
|
127.8 ± 12.8
|
36.3 ± 7.4#
|
48.1 ± 11.7#
|
|
100 μM
|
20.5 ± 5.9#
|
29.3 ± 12.1*
|
17.3 ± 7.1#
|
19.9 ± 12.5#
|
17.1 ± 6.1#
|
53.6 ± 6.8#
|
21.0 ± 6.3#
|
45.4 ± 12.6#
|
- HeLa or non-transformed retinal pigment epithelial cells that stably express human telomerase reverse transcriptase (TERT) were seeded at 250 cells/mL and then treated for 7 days with 25-100 uM of the indicated test compound. The proliferation in treated cells is shown as a percentage of control cells (DMSO only set at 100%) following analysis using the WST-1 assay. Data represent mean ± SEM from 3 experiments. * and # indicates statistical significance compared to untreated controls, p ≤ 0.05 and p ≤ 0.01, respectively
